Plasmic degradation modulates activity of fibrinogen-bound fibroblast growth factor-2

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 6, 2003, Pages 1271-1277

  Sahni, A ^a   Francis, C W ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

FGF 2; Fibrinogen; Plasmin

Indexed keywords

CALCIUM; FIBRINOGEN; FIBROBLAST GROWTH FACTOR 2; PEPTIDE FRAGMENT; PLASMIN;

ARTICLE; BINDING SITE; CELL DIVISION; CYTOLOGY; HUMAN; METABOLISM; PROTEIN BINDING; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

BINDING SITES; CALCIUM; CELL DIVISION; ENDOTHELIUM, VASCULAR; FIBRINOGEN; FIBROBLAST GROWTH FACTOR 2; HUMANS; PEPTIDE FRAGMENTS; PLASMIN; PROTEIN BINDING; UMBILICAL VEINS;

EID: 2142751534     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00228.x     Document Type: Article

References (52)

1. Cheresh DA, Berliner SA, Vicente V, Ruggeri ZM. Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell 1989; 58: 945-53.
2. Suehiro K, Gailit J, Plow EF. Fibrinogen is a ligand for integrin alpha5beta1 on endothelial cells. J Biol Chem 1997; 272: 5360-6.
3. Barbieri B, Balconi G, Dejana E, Donati MB. Evidence that vascular endothelial cells can induce the retraction of fibrin clots. Proc Soc Exp Biol Med 1981; 168: 204-7.
4. Schleef RR, Birdwell CR. The effect of fibrin on endothelial cell migration in vitro. Tissue Cell 1982; 14: 629-36.
5. Kaplan KL, Mather T, DeMarco L, Solomon S. Effect of fibrin on endothelial cell production of prostacyclin and tissue plasminogen activator. Arteriosclerosis 1989; 9: 43-9.
6. Ramsby ML, Kreutzer DL. Fibrin induction of tissue plasminogen activator expression in corneal endothelial cells in vitro. Invest Ophthal Vis Sci 1993; 34: 3207-19.
7. Qi J, Kreutzer DL. Fibrin activation of vascular endothelial cells. Induction of IL-8 expression. J Immunol 1995; 155: 867-76.
8. Fukao H, Ueshima S, Tanaka N, Okada K, Matsuo O. Suppression of plasminogen activator inhibitor 1 release by fibrin from human umbilical vein endothelial cells. Thromb Res Suppl 1990; 10: 11-20.
9. Fukao H, Matsumoto H, Ueshima S, Okada K, Matsuo O. Effects of fibrin on the secretion of plasminogen activator inhibitor-1 from endothelial cells and on protein kinase C. Life Sci 1995; 57: 1267-76.
10. Ribes JA, Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest 1987; 79: 117-23.
11. Ribes JA, Ni F, Wagner DD, Francis CW. Mediation of fibrin-induced release of von Willebrand factor from cultured endothelial cells by the fibrin beta chain. J Clin Invest 1989; 84: 435-42.
12. Chalupowicz DG, Chowdhury ZA, Bach TL, Barsigian C, Martinez J. Fibrin II induces endothelial cell capillary tube formation. J Cell Biol 1995; 130: 207-15.
13. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992; 59: 115-65.
14. Hartung H, Feldman B, Lovec H, Coulier F, Birnbaum D, Goldfarb M. Murine FGF-12 and FGF-13: expression in embryonic nervous system, connective tissue and heart. Mech Dev 1997; 64: 31-9.
15. Araki S, Simada Y, Kaji K, Hayashi H. Role of protein kinase C in the inhibition by fibroblast growth factor of apoptosis in serum-depleted endothelial cells. Biochem Biophys Res Commun 1990; 172: 1081-5.
16. Terranova VP, DiFlorio R, Lyall RM, Hic S, Friesel R, Maciag T. Human endothelial cells are chemotactic to endothelial cell growth factor and heparin. J Cell Biol 1985; 101: 2330-4.
17. Presta M, Moscatelli D, Joseph-Silverstein J, Rifkin DB. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol Cell Biol 1986; 6: 4060-6.
18. Klein S, Roghani M, Rifkin DB. Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. Exp Suppl 1997; 79: 159-92.
19. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
20. Moscatelli D, Presta M, Rifkin DB. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration. Proc Natl Acad Sci USA 1986; 83: 2091-5.
21. Gualandris A, Presta M. Transcriptional and posttranscriptional regulation of urokinase-type plasminogen activator expression in endothelial cells by basic fibroblast growth factor. J Cell Physiol 1995; 162: 400-9.
22. Mignatti P, Mazzieri R, Rifkin DB. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J Cell Biol 1991; 113: 1193-201.
23. Dionne CA, Crumley G, Bellot F, Kaplow JM, Searfoss G, Ruta M, Burgess WH, Jaye M, Schlessinger J. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J 1990; 9: 2685-92.
24. Roghani M, Mansukhani A, Dell'Era P, Bellosta P, Basilico C, Rifkin DB, Moscatelli D. Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J Biol Chem 1994; 269: 3976-84.
25. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J, Lax I. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994; 79: 1015-24.
26. Sommer A, Rifkin DB. Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol 1989; 138: 215-20.
27. Sahni A, Odrljin T, Francis CW. Binding of basic fibroblast growth factor to fibrinogen and fibrin. J Biol Chem 1998; 273: 7554-9.
28. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000; 96: 3772-8.
29. Sahni A, Sporn LA, Francis CW. Potentiation of endothelial cell proliferation by fibrin(ogen)-bound fibroblast growth factor-2. J Biol Chem 1999; 274: 14936-41.
30. Sahni A, Baker CA, Sporn LA, Francis CW. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation. Thromb Haemost 2000; 83: 736-41.
31. Engvall E, Ruoslahti E. Binding of soluble form of fibroblast surface protein, fibronectin, to collagen. Int J Cancer 1977; 20: 1-5.
32. Bunce LA, Sporn LA, Francis CW. Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the beta chain. J Clin Invest 1992; 89: 842-50.
33. Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein inWeibel-Palade bodies of human endothelial cells. J Cell Biol 1982; 95: 355-60.
34. Marder VJ, Shulman NR, Carroll WR. High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem 1969; 244: 2111-9.
35. Southan C, Thompson E, Panico M, Etienne T, Morris HR, Lane DA. Characterization of peptides cleaved by plasmin from the C-terminal polymerization domain of human fibrinogen. J Biol Chem 1985; 260: 13095-101.
36. Dang CV, Ebert RF, Bell WR. Localization of a fibrinogen calcium binding site between gamma-subunit positions 311 and 336 by terbium fluorescence. J Biol Chem 1985; 260: 9713-9.
37. Odrljin TM, Rybarczyk BJ, Francis CW, Lawrence SO, Hamaguchi M, Simpson-Haidaris PJ. Calcium modulates plasmin cleavage of the fibrinogen D fragment gamma chain N-terminus: mapping of monoclonal antibody J88B to a plasmin sensitive domain of the gamma chain. Biochim Biophys Acta 1996; 1298: 69-77.
38. Varadi A, Scheraga HA. Localization of segments essential for polymerization and for calcium binding in the gamma-chain of human fibrinogen. Biochemistry 1986; 25: 519-28.
39. Chen R, Doolittle RF. Cross-linking sites in human and bovine fibrin. Biochemistry 1971; 10: 4487-91.
40. Kloczewiak M, Timmons S, Lukas TJ, Hawiger J. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry 1984; 23: 1767-74.
41. Lam SC, Plow EF, Smith MA, Andrieux A, Ryckwaert JJ, Marguerie G, Ginsberg MH. Evidence that arginyl-glycyl-aspartate peptides and fibrinogen gamma chain peptides share a common binding site on platelets. J Biol Chem 1987; 262: 947-50.
42. Erban JK, Wagner DD. A 130-kDa protein on endothelial cells binds to amino acids 15-42 of the B beta chain of fibrinogen. J Biol Chem 1992; 267: 2451-8.
43. Bach TL, Barsigian C, Chalupowicz DG, Busler D, Yaen CH, Grant DS, Martinez J. VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp Cell Res 1998; 238: 324-34.
44. Belew M, Gerdin B, Porath J, Saldeen T. Isolation of vasoactive peptides from human fibrin and fibrinogen degraded by plasmin. Thromb Res 1978; 13: 983-94.
45. Rowland FN, Donovan MJ, Picciano PT, Wilner GD, Kreutzer DL. Fibrin-mediated vascular injury. Identification of fibrin peptides that mediate endothelial cell retraction. Am J Pathol 1984; 117: 418-28.
46. Skogen WF, Senior RM, Griffin GL, Wilner GD. Fibrinogen-derived peptide B beta 1-42 is a multidomained neutrophil chemoattractant. Blood 1988; 71: 1475-9.
47. Senior RM, Skogen WF, Griffin GL, Wilner GD. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest 1986; 77: 1014-9.
48. Richardson DL, Pepper DS, Kay AB. Chemotaxis for human monocytes by fibrinogen-derived peptides. Br J Haematol 1976; 32: 507-13.
49. Andersson RG, Saldeen K, Saldeen T. A fibrin(ogen) derived pentapeptide induces vasodilation, prostacyclin release and an increase in cyclic AMP. Thromb Res 1983; 30: 213-8.
50. Gerdin B, Lindeberg G, Ragnarsson U, Saldeen T, Wallin R. Structural requirements for microvascular permeability-increasing ability of peptides. Studies on analogues of a fibrinogen pentapeptide fragment. Biochim Biophys Acta 1983; 757: 366-70.
51. Bini A, Kudryk BJ. Fibrinogen and fibrin in the arterial wall. Thromb Res 1994; 75: 337-41.
52. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56: 2428-33.